Opus Genetics Inc. Common Stock (IRD)

About IRD

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associa…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

27

Website

opusgtx.com/

Fundamentals

1-day range

$3.76$4.08

Market cap

$307.14M

P/E (trailing)

—

P/E (forward)

-5.74

EPS (trailing)

$-1.32

Dividend yield

—

Beta

0.67

Avg. volume

938.8K

Dividend pay date

November 6, 2020

Forecasts

18 analyst ratings

Opus Genetics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IRD

  Opus Genetics Inc. Common Stock

  $3.7

  ▼ 3.90%
  Market cap $307.14MP/E —
  $1.17$5.81
• VNDA

  Vanda Pharmaceuticals Inc. Common Stock

  $5.29

  ▼ 2.76%
  Market cap $307.59MP/E —
  $4.27$9.94
• ORGO

  Organogenesis Holdings Inc. Class A Common Stock

  $1.74

  ▼ 0.00%
  Market cap $310.11MP/E 84.95
  $1.54$7.08
• IMRX

  Immuneering Corporation Class A Common Stock

  $4.99

  ▼ 4.22%
  Market cap $288.55MP/E —
  $3.86$10.08
• FULC

  Fulcrum Therapeutics Inc. Common Stock

  $3.85

  ▲ 0.00%
  Market cap $287.64MP/E —
  $2.83$15.74
• FHTX

  Foghorn Therapeutics Inc. Common Stock

  $6

  ▼ 3.54%
  Market cap $327.04MP/E —
  $3.27$7.61
• ALXO

  ALX Oncology Holdings Inc. Common Stock

  $2

  ▼ 2.44%
  Market cap $283.93MP/E —
  $0.96$2.66

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
  benzinga · 8/7/2026
• RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
  Benzinga · 8/7/2026
• Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares
  Benzinga · 8/7/2026
• Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
  Benzinga · 8/6/2026
• Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease
  Benzinga · 8/3/2026

• George Magrath · July 23, 2026 · Sale

  9.5K @ $2.95
• Robert E. Gagnon · July 23, 2026 · Sale

  7.8K @ $2.95
• Joseph K. Schachle · July 23, 2026 · Sale

  4.6K @ $2.94
• Benjamin R. Yerxa · July 23, 2026 · Sale

  7.4K @ $2.97
• Foundation Fighting Blindness Retinal Degeneration Fund · May 18, 2026 · Sale

  1.70M @ $4.35
• Rabourn Amy Zaremba · April 23, 2026 · Sale

  1.6K @ $5.2
• George Magrath · April 23, 2026 · Sale

  9.5K @ $5.22
• Ashwath Jayagopal · April 23, 2026 · Sale

  7.5K @ $5.19
• Robert E. Gagnon · April 23, 2026 · Sale

  7.8K @ $5.18
• Joseph K. Schachle · April 23, 2026 · Sale

  4.7K @ $5.22
• Benjamin R. Yerxa · April 23, 2026 · Sale

  7.5K @ $5.24
• Richard J. Rodgers · April 20, 2026 · Grant

  24.4K
• James S. J. Manuso · April 20, 2026 · Grant

  24.4K
• Adrienne L. Graves · April 20, 2026 · Grant

  24.4K
• Cam Gallagher · April 20, 2026 · Grant

  24.4K

Institutional Ownership

March 31, 2026

Total shares held

45.23M

Total value held

$202.56M

Institutional holders

77